510(k), De Novo, or PMA? Telling Them Apart with Real FDA Records
The marketing draft lands in your inbox with "FDA-approved" in the headline and a K number in the footnote. If you work in regulatory affairs, you have corrected that sentence before. Here is the background in a form you can forward.
At a high level, one useful way to tell the three pathways apart is to ask what the device is compared against. A 510(k) compares the device to a legally marketed predicate, and FDA clears it. A De Novo is for a low-to-moderate-risk device with no predicate to compare against, and FDA grants it a new classification. A PMA, for Class III devices, puts valid scientific evidence of safety and effectiveness in front of FDA rather than a comparison, and FDA approves it.
The submission number tells you which: K for 510(k), DEN for De Novo, P for PMA. Below we open one record of each, SKOUT system (K213686), DeepView AI System (DEN250028) and Claire OCT System (P250008), and look at what each public document says.
The three pathways on one table
This is a general summary based on FDA's public information. Which pathway actually applies also depends on the device's classification, its risk, and whether the classification is exempt from 510(k).
| 510(k) | De Novo | PMA | |
|---|---|---|---|
| Typical device | Most Class II (some Class I) | Low-to-moderate risk with no predicate | Class III |
| What you show | Substantial equivalence to a predicate | That general controls alone, or general and special controls, provide reasonable assurance of safety and effectiveness | Valid scientific evidence providing reasonable assurance of safety and effectiveness |
| FDA's decision | Cleared | Granted | Approved |
| Main public document | 510(k) Summary | Classification Order; Decision Summary where available | Summary of Safety and Effectiveness Data (SSED) |
| Classification | The device enters an existing classification; usually no new classification | Establishes a new Class I or Class II classification, with a regulation and product code, and special controls if Class II | An approval for that device |
Among these three pathways, De Novo is the one that establishes a new device type. That difference shows up clearly in the SKOUT and DeepView records.
510(k): what did SKOUT system compare against?
SKOUT system (K213686) is a 510(k) from Iterative Scopes Inc. (now Iterative Health), cleared on August 12, 2022, under product code QNP (Gastrointestinal Lesion Software Detection System, 21 CFR 876.1520). "21 CFR" refers to Title 21 of the Code of Federal Regulations, where FDA's regulations are codified. Its Indications for Use describe software that detects potential colorectal polyps in real time during colonoscopy, to "assist qualified and trained gastroenterologists."
A 510(k) Summary is easiest to read in three steps: what the device was compared against (the predicate), where it is the same and where it differs (indications and technological characteristics), and how the differences were addressed (performance testing).
SKOUT's predicate was another company's device: GI Genius from Cosmo Artificial Intelligence – AI, Ltd., granted De Novo in 2021 (DEN200055). That De Novo is what created product code QNP. SKOUT, in other words, entered a classification a competitor had opened, using the competitor's device as its predicate.
The comparison in the Summary lists what the two share: AI-based polyp detection, the same patient population, and visual markers overlaid on the endoscopic video. The differences it lists are the markers themselves (a blue rectangle for SKOUT, a green square with an audio alert for GI Genius) and a video display switch on SKOUT.
Having a predicate did not mean doing without clinical data. SKOUT's 510(k) was supported by a multicenter, prospective, randomized controlled trial, with adenomas per colonoscopy (APC) among the endpoints. For AI devices, FDA may expect clinical performance data even when a predicate of the same type exists.
De Novo: DeepView's name is nowhere in its classification
DeepView AI System (DEN250028) is a De Novo request from Spectral MD, Inc., granted on May 21, 2026. The grant established a Class II classification under 21 CFR 878.1840, product code SHY, with the classification name "software-aided adjunctive diagnostic device for use by healthcare providers in skin wound assessment."
The word DeepView does not appear in that name. What it describes is a device type. In a De Novo, FDA authorizes one product and, in the same decision, defines the type it belongs to. That is why a De Novo record has no predicate line. The Classification Order is where you read the classification name, the class, the regulation and the special controls.
For DEN250028, the Indications for Use are specific to burns: the software detects and highlights deep burn tissue in images. The classification name covers skin wound assessment more broadly. The Classification Order sets seven special controls, among them clinical performance validation, software verification and validation, human factors assessment and labeling. We could not find a Decision Summary on FDA's site as of October 4, 2026.
A device classified through De Novo may later serve as a predicate for a 510(k), where applicable. A follow-on device would have to meet the special controls and demonstrate substantial equivalence. Not every De Novo results in Class II, either. When general controls alone are sufficient, the device type is placed in Class I.
PMA: the SSED is about the evidence
Claire OCT System (P250008) is a PMA from Perimeter Medical Imaging AI, Inc., approved on March 3, 2026, under product code SHH. It images the margins of tissue excised during breast lumpectomy using optical coherence tomography (OCT), and an AI detection algorithm marks areas suspicious for cancer. Its Indications for Use describe an adjunctive tool, used concurrently with the physician's interpretation of the images and together with standard methods of margin evaluation.
For a PMA, the document to open is the SSED. It summarizes the indications, the device description, the nonclinical and clinical studies, and FDA's conclusions on safety and effectiveness. Claire's SSED lists nonclinical testing that includes laser safety, software verification, cybersecurity and usability, and reports a multicenter randomized controlled trial. The primary endpoint compared unaddressed positive margins after standard-of-care evaluation alone with standard of care plus the device.
FDA decides a PMA on the body of valid scientific evidence, nonclinical and clinical. What that evidence must include depends on the device, but, as with Claire, a clinical study is often at the center.
DeepView and Claire are both AI that supports a clinician's judgment. One went through De Novo into Class II, the other through PMA as a Class III device. Calling a device adjunctive does not settle its pathway or its class.
Which pathway is yours?
We suggest working through these questions in order.
- Does the device fit an existing classification, with an appropriate predicate? If so, consider whether you can demonstrate substantial equivalence. Check whether the classification is exempt from 510(k). Devices in classifications created by De Novo can be predicates too.
- No predicate, but low-to-moderate risk? De Novo is the candidate. Product code QNP itself was created when GI Genius (DEN200055) was granted on April 9, 2021, and SKOUT, from a different company, was later cleared through a 510(k) with GI Genius as its predicate.
- Class III? Then PMA, with scientific evidence that often includes a clinical study.
Many devices sit on the line between 1 and 2. The Pre-Submission (Q-Sub) program lets you ask FDA before you file, and if the classification itself is unclear, a 513(g) request for information gets FDA's view on it.
Only a PMA is approved
Back to the draft in your inbox. FDA clears a 510(k). "Approved" belongs to the PMA, and "granted" to De Novo. For a 510(k) device, write "FDA cleared"; for a De Novo, "granted De Novo authorization" or simply "authorized."
This is not only a matter of style. Under 21 CFR 807.97, a 510(k) clearance does not in any way denote official approval of the device, and any representation that creates an impression of official approval because of the clearance is misleading and constitutes misbranding. The same care applies to investor decks, distributor briefings and job postings, anywhere a K number is turned into a sentence.
Put the three records side by side
Every device page on this site shows the Pathway. Star (☆) the three records in this article, tick "Compare" on them in My Workspace, and open the comparison table. Because the public documents differ by pathway, sections such as Device Description and Clinical fill in differently for each one.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles